Croda International PLC (LON:CRDA) Rating Reemphasized by research analysts JP Morgan Cazenove Today

Share

Croda International PLC (LON:CRDA) Rating Reaffirmed

In an analyst research report issued to investors and clients by JP Morgan Cazenove on Wednesday, 2 December, The Rating on Croda International PLC (LON:CRDA) shares of a ‘Neutral’ was reconfirmed.

From a total of 18 analysts covering Croda International PLC (LON:CRDA) stock, 6 rate it a ”Buy”, 2 a “Sell”, and 9 a ”Hold”. This means that 35% of the ratings are positive. The highest target price is GBX 3400 while the lowest target price is GBX 1800. The mean of all analyst targets is GBX 2927.06 with a 4.18% above today’s (GBX 2875) stock price. Croda International PLC was the topic of 33 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Morgan Stanley maintained shares on December 1 with “Overwt/In-Line” rating. Barclays Capital maintained shares with “Equalweight” rating and GBX 3100 target share price in a report from a November 13. Goldman Sachs maintained CRDA stock in a recent report from November 30 with “Buy” rating. Berenberg maintained the rating on November 11. Berenberg has a “Hold” rating and a GBX 2850 price target on shares. Finally, UBS maintained the stock with “Sell” rating in a report issued on a November 25.

The stock increased 0.24% or GBX 7 on December 1, striking GBX 2875. Approximately 317,046 shares of stock traded hands or 28.47% up from the average. Croda International Plc (LON:CRDA) has risen 3.12% since May 5, 2015 and is uptrending. It has outperformed by 4.74% the S&P500.

Croda International PLC (LON:CRDA) Rating Reemphasized by research analysts JP Morgan Cazenove Today

Croda International Plc is a United Kingdom specialty chemical manufacturer. The company has a market cap of 3.77 billion GBP. The Company’s divisions include Personal Care, Life Sciences, Performance Technologies and Industrial Chemicals. It has 22.34 P/E ratio. The Firm is a supplier of specialty ingredients for the personal care industry.

COMMENTS: